SMC product assessment decisions

The Scottish Medicines Consortium (SMC) has announced its decision on the following therapies:

ACCEPTED FOR USE

  • Xolair (omalizumab) as add-on therapy in severe persistent allergic asthma.
  • Januvia (sitagliptin) for treatment of type II diabetes mellitus in combination with metformin.
  • Budenofalk (budesonide) for ulcerative colitis of the rectum and sigmoid colon.
  • Invanz (ertapenum) for prophylaxis of surgical site infection following elective colorectal surgery.
  • Atimos Modulite (formoterol) for coronary obstructive pulmonary disease.

REJECTED FOR USE

  • Cipralex (escitalopram) for obsessive compulsive disorder.
  • Prialt (ziconotide) for treatment of severe, chronic pain.
  • Cystadane (betaine) as adjunctive treatment of homocystinuria.

Further information: The Scottish Medicines Consortium

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

First COVID-19 vaccine approved for use in the UK from next week

First COVID-19 vaccine approved for use in the UK from next week

The MHRA has approved the COVID-19 vaccine developed...

SGLT2 inhibitors summarised in new MIMS table

SGLT2 inhibitors summarised in new MIMS table

Prescribers can quickly compare key features and benefits...